摘要
目的：比较齐拉西酮、利培酮口服液与氟哌啶醇治疗精神分裂症急性期兴奋激越的疗效及安全性。方法：齐拉西酮30例,剂量范围20～100 mg/d;利培酮口服液组29例,剂量范围1～6 mg/d;氟哌啶醇30例,剂量范围5～30 mg/d,用PANSS及TESS评定疗效和不良反应,观察期2周。结果：齐拉西酮和利培酮口服液组PANSS兴奋激越因子总分减分率在第1周末及第2周末稍差于氟哌啶醇组,在针对每个兴奋因子方面三组药物各有优势,但齐拉西酮和利培酮口服液组的药物不良反应显著低于氟哌啶醇组。结论：齐拉西酮和利培酮口服液治疗精神分裂症伴兴奋激越症状患者疗效较肯定,不良反应较小,安全性好。
Objective：To compare the efficacy and safety of Ziprasidone,Risperidone and Haloperidol in the treatment of the acute phrase of schizophrenia.Methods：30 cases were treated with Ziprasidone in a regimen of 20～100 mg/d,29 cases were treated with Risperidone in a regimen of 1～6 mg/d and 30 cases were treated with haloperidol in a regimen of 5～30 mg/d.PANSS and TESS were used to measure the efficacy and safety for 2 weeks.Results： It was found that the total efficacy of olanzapine in treating the acute phrase of schizophrenia was similar to haloperidol.The olanzapine group was superior to the haloperidol group in the first（t=3.16,P〈0.05） and second week（t=3.59,P〈0.05） of PANSS Excited Components＇ subtraction.The Ziprasidone and Risperidone group had significantly fewer side effects.Conclusions： Ziprasidone and Risperidone show a satisfactory effect and safety in treating the acute phrase of schizophrenia.
出处
《中国民康医学》
2008年第23期2753-2756,共4页
Medical Journal of Chinese People’s Health
